Primary deep vein thrombosis in an upper limb : a retrospective study with an emphasis on the pathogenesis and late sequelae by Arnhjort, Thomas
From the Department of Clinical Science and Education, 
Södersjukhuset 
Karolinska Institutet, Stockholm, Sweden 
PRIMARY DEEP VEIN THROMBOSIS IN AN 
UPPER LIMB: A RETROSPECTIVE STUDY 
WITH AN EMPHASIS ON THE PATHOGENESIS 
AND LATE SEQUELAE 
Thomas Arnhjort, MD 
 
 
 Stockholm, 2016  
 
 All previously published papers were reproduced with the permission of the publisher. 
Published by Karolinska Institutet. 
Printed by AJ E-print AB 
© Thomas Arnhjort, 2016 
ISBN 978-91-7676-324-7 
PRIMARY DEEP VEIN THROMBOSIS IN AN UPPER LIMB: A 
RETROSPECTIVE STUDY WITH AN EMPHASIS ON THE 
PATHOGENESIS AND LATE SEQUELAE 
 
THESIS FOR DOCTORAL DEGREE (PhD) 
For the PhD degree at Karolinska Institutet. The thesis is to be defended in 
the Great Aula at Södersjukhuset. 
Friday, December 16, 2016, 9 a.m. 
 
By 
Thomas Arnhjort 
Principal Supervisor: 
Associate Professor Gerd Lärfars 
Karolinska Institutet 
Department of Clinical Science and Education, 
Södersjukhuset 
Division of Internal Medicine,  
Södersjukhuset 
 
Co-supervisor: 
Associate Professor Stefan Rosfors 
Department of Clinical Science and Education, 
Södersjukhuset 
Division of Clinical Physiology,  
Södersjukhuset 
 
  
Opponent: 
Professor Bengt I. Eriksson 
University of Gothenburg  
Institute of Clinical Sciences 
Department of Orthopedics 
 
Examination Board: 
Associate Professor Bengt Lindblad 
Lund University  
Department of Vascular Diseases 
    
Associate Professor Hans Johnsson 
Karolinska Institutet  
Department of Medicine, Solna 
Division of Emergency Medicine 
 
Associate Professor Helene Zachrisson 
University of Linköping 
Department of Medical and Health Sciences, 
Clinical Physiology 
Division of Cardiovascular Medicine   
 
 
 
  
 
 
 
 
 
 
 
 
To Göran, the love of my life 
  
  
 
 
  
ABSTRACT 
Background:  Upper extremity deep vein thrombosis (UEDVT) is an uncommon disease with an incidence of 
1–11% of all deep vein thrombosis. UEDVT can be classified into two groups, primary and secondary UEDVT. 
Primary UEDVT includes idiopathic and effort-related UEDVT. Secondary UEDVT is caused by central venous 
devices, trauma, and cancer. This thesis is focused on primary UEDVT. 
Aim: This project emerged from a clinical question when we started to review our guidelines for deep vein 
thrombosis at the Emergency Department at Södersjukhuset, Stockholm. The overall aim of this thesis was to 
increase the level of knowledge concerning primary UEDTV. 
 
Patients: Thirty-one patients (23 females, 8 males) with primary UEDVT were enrolled for Papers I. For paper 
II there was thirty-two patients (23 females and 9 males) included. Fifteen of these patients agreed to participate 
in the third study, the MRI Study, in which a control group of 15 healthy volunteers was also included. 
The fourth paper is a retrospective case-control study based on data from the Swedish National Patient Register 
(NPR) and comprises 25 patients with primary UEDVT. 
 
Methods: In Paper I, the patients were evaluated using interviews, clinical examinations, computerized strain-
gauge plethysmography, and color duplex ultrasound (CDU) imaging. The degree of postthrombotic syndrome 
(PTS) was rated according to the Villalta score. For the second paper, the Villalta score was supplemented with 
the DASH test (Disability of the arm shoulder and hand). The visual analog scale (VAS) was used to estimate 
pain and disability. An arm exercise capacity test was performed to evaluate working capacity. Blood samples 
were taken for analyses of factor V Leiden and common coagulation factors. 
In Paper III, the subclavian region (the costoclavicular distance) and vessel area of the subclavian vein were 
examined using magnetic resonance imaging (MRI). The MRI was performed with the arms in two positions: 
alongside and elevated. PTS and disability were quantified with the Villalta and DASH scores. 
The 25 patients in the fourth paper were matched on an individual basis with 474 controls (patients with acute 
appendicitis) in relation to sex, age at the index point, and the year of the index point. Comorbidity was 
described as the number of unique ICD codes (diagnoses) registered in the NPR from the index point to the end 
of year 2011.  
 
Results: Paper I. The rate of venous emptying was significantly lower in the arms with DVTs than in the 
contralateral arms. Fifty-eight percent had a residual thrombus and seventy-five percent of the patients had some 
morphologic abnormality in the thrombotic vein. There was no statistically significant relationship between the 
plethysmographic and duplex findings. No significant difference in the relationship between the postthrombotic 
syndrome score and duplex findings or venous emptying was evident.  
Paper II. None of the patients developed malignancies, pulmonary embolism, or recurrent UEDVT. Twenty-
eight percent of the patients had mild to moderate PTS according to the scoring instruments. The prevalence of 
thrombophilia was 40%; the most frequent disorders were the mutation of the gene for factor V Leiden (19%) 
and elevated fibrinogen (22%). 
Paper III. The costoclavicular distance was significantly narrower in the patients than in the controls with the 
arms alongside the body, but there was a significant difference only in the left arm with the arms elevated. Area 
of the subclavian vein: on comparing the patients’ non-thrombotic arm with that of the controls, there was a 
significant difference only with the arms in the supine position. Measurements of disability: there was a high 
correlation between DASH, the Villalta score, and VAS, but there was no correlation between the MRI 
measurements and the patients’ symptoms. 
Paper IV. The 25 cases and 474 controls, 48% male and 52% female, had a mean age at the index point of 48 
years (range, 20–80, SD 17.5). The mean follow-up time was 8 years (range, 5.7–9). There was no significant 
difference between patients and controls regarding the frequency of reported unique ICD codes in the NPR when 
all ICD codes were analyzed together, but there was a significant difference for codes related to symptoms from 
the blood and blood-forming organs, the endocrine and metabolic systems, disease of the nervous and circulatory 
systems, and skin and musculoskeletal systems. There was no difference in ICD codes relating to malignancies. 
The cases had a significantly higher number of healthcare contacts. 
Conclusions 
 Primary UEDVT is a rather benign disease with a low rate of recurrences, but with a non-negligible 
proportion of the postthrombotic syndrome.   
 Fifty-eight percent had a residual thrombus. Seventy-five percent of the patients had some morphologic 
abnormality in the thrombotic vein, which was detectable with CDU. The rate of venous emptying was 
significantly lower in the arms with DVTs than in the contralateral arms. 
 There was no correlation between PTS and plethysmography findings, area of the subclavian vein, and 
morphologic abnormalities detected by CDU.  
 The frequency of coagulation disorders was about 40%; the most common disorders in our study 
population were mutations of factor V Leiden. 
 There seemed to be some influence regarding the anatomy of the thoracic outlet and the development of 
both effort-related and idiopathic UEDVT. 
 The rate of malignancies seems to be in line with that of the general population. 
 It is extremely important to validate data from the National Patient Register with the medical records 
especially when there is no unique ICD-code.  
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2 LIST OF ABBREVIATIONS 
 
ACCP American College of Chest Physicians 
ADP Adenosine diphosphate 
APC Activated protein C 
ASA Acetylsalicylic acid 
AT  Antithrombin 
BMI Body mass index 
CDU Color duplex ultrasound 
CEAP Clinical, etiology, anatomy, pathophysiology  
CVC Central venous catheter 
DASH Disability of the arm, shoulder, and hand 
DVT  Deep vein thrombosis 
FDP Fibrin/fibrinogen degradation products 
GP Glycoprotein 
HRT Hormone replacement therapy 
LEDVT Lower extremity deep vein thrombosis 
LMWH  Low molecular weight heparin 
MRI Magnetic resonance imaging 
MRV Magnetic resonance venography 
NPR National Patient Register 
PA Plasminogen activator 
PAI Plasminogen activator inhibitor 
PE Pulmonary embolism 
PF Platelet factor 
PICCs Peripherally inserted central venous catheters 
PRN Personal registration number   
PSS Paget-Schrotter syndrome 
PTS Postthrombotic syndrome 
TOS Thoracic outlet syndrome 
UEDVT Upper extremity deep vein thrombosis 
VAS Visual analog scale 
VCSS Venous clinical severity score  
VE Venous emptying  
VKA Vitamin K antagonist 
VTE Venous thromboembolism 
VV Venous volume 
vWF von Willebrand factor 
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3 INTRODUCTION 
Upper extremity deep vein thrombosis (UEDVT) can be classified into two groups, primary 
and secondary. UEDVT, especially the primary type, is an uncommon disease which mostly 
affects young to middle-aged patients. This thesis is focused on primary UEDVT.  
     This project emerged from a clinical question which arose when we started to review our 
guidelines for deep vein thrombosis at the Emergency Department of Södersjukhuset. The 
question was “How to handle patients with deep vein thrombosis of the upper extremity?” 
The first tentative answer was “We do as we do with the legs.” This rather simple and 
unscientific answer gave rise to further questions and we started to look into the literature on 
the topic and one of our first findings was that there was no clear answer to our question. 
There were no consistent answers regarding investigation, examination, and treatment. Some 
authors advocated such active treatment as thrombolysis, while others considered 
conventional anticoagulant therapy to be the most suitable. 
.
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4 BACKGROUND 
4.1 VENOUS THROMBOEMBOLISM 
Deep vein thrombosis (DVT) can affect different veins in the body. The incidence of DVT is 
estimated to be 1.6 per 1000 inhabitants per year for both males and females [1]. The 
incidence of venous thromboembolism (VTE) increases with age, the highest incidence 
occurring among women over 85 years of age [2]. Several studies have shown that 40–50% 
of the patients with symptomatic proximal DVT have ventilation-perfusion lung scan 
findings associated with a high probability of pulmonary embolism (PE) [3-7].    
DVT is not only a severe disease because of the risk for PE, it can also cause long-term 
sequelae in form of postthrombotic syndrome (PTS) [8]. More than 30 % of all patients with 
DVT will develop PTS [9].  
      The most common location of VTE is in the lower extremity with a wide spectrum of 
severity from a small, limited clot in the calf to marked thrombosis extending into the pelvic 
veins.  
      Typical symptoms of DVT are pain and redness or discoloration of the skin, prominent 
veins, swelling, and tenderness. DVT can also be asymptomatic; the proportion is unknown, 
but significant. Due to the lack of symptoms, the patient does not seek treatment and the clot 
is believed to resolve spontaneously [5]. 
4.1.1 Coagulation and hemostasis 
Normal coagulation involves pathways of enzymatic reactions that start as a response to a 
damaged endothelium. The endpoint is the formation of fibrin, which stabilizes the platelet 
clot. Both collagen and tissue factor can activate the platelets; see below – the procoagulant 
system. Simultaneously, the anticoagulant system starts to avoid pathological intravascular 
coagulation – the anticoagulant system. 
      Hemostasis is defined as a balance between the two systems or the process that maintains 
the integrity of the circulatory system after vascular damage [10]. 
4.1.1.1 Normal coagulation 
The procoagulant system 
When the endothelium is damaged there will be a contraction of the vessel and formation of 
an unstable thrombocyte clot, i.e., the primary hemostasis.  
      There are different ways to activate the platelets. Collagen (the intrinsic pathway) from 
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damaged endothelium attracts the von Willebrand factor (vWF) which circulates in the blood. 
This attraction, combined with receptor glycoproteins (GP VI-Ib-V-IX), activates the 
platelets and causes them to adhere and form a clot, the thrombocyte clot. Tissue factor 
(extrinsic pathway), normally located inside of the vessel wall, can activate the platelets by 
forming a complex with factor VIIa, leading to thrombin generation and more platelets being 
captured on the vessel wall. This second way of platelet activation is independent of the von 
Willebrand factor. 
      Inside the platelet are granules which contain several factors and components (adenosine 
diphosphate [ADP], fibrinogen, FXIII, FV, vWF, serotonin, platelet factor 4 [PF-4] and beta 
thromboglobulin) which are necessary for homeostasis. ADP is the most important factor for 
further platelet aggregation, but it also has a role on the thrombocyte membrane aimed at 
presenting the glycoprotein complex (GPIIb/IIIa). This complex has the function of a fibrin 
receptor and can attach more platelets. The thrombocytic clot is still permeable and might be 
flushed away by the bloodstream.  
      During hemostasis, the prostaglandins are activated, the most important step being the 
formation of thromboxane A2, which promotes the aggregation of thrombocytes and also has 
a contraction effect on the vessel. Acetylsalicylic acid (ASA) has an inhibitory effect on the 
production of thromboxane A2. 
      The clot becomes stable when fibrinogen converts to fibrin. An important step in this 
process is the formation of activated factor X (FXa). FXa, together with calcium, factor Va, 
and phospholipids, converts prothrombin to thrombin, which makes the platelets stickier and 
the thrombocyte clot more stable. Thrombin also generates fibrin out of fibrinogen. Fibrin, 
together with factor XIII, completes the secondary hemostasis (Figure 1).  
 
Figure 1. The role of factor X. 
Thirteen circulating coagulations factors have been identified and are involved in the 
complex cascade of various steps to maintain hemostasis. All coagulation factors are 
synthesized in the liver, except factors V and VIII, which are synthesized in the thrombocytes 
and the endothelium, respectively. Factors II, VII, IX, and X are vitamin K-dependent. 
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The coagulation process starts immediately when there is a trauma to a vessel, so as to stop 
the bleeding. The process can also be triggered by other mechanisms, such as 
microorganisms and cancer tumors, thereby resulting in pathological intravascular 
coagulation. 
The anticoagulant system 
The most important inhibitor of the procoagulant system is protein C, the role of which is to 
reduce the activity of thrombin and thereby also inhibit the formation of fibrin. Protein C is a 
vitamin K-dependent pro-enzyme that is slowly activated by thrombin. Activated protein C 
(APC), together with protein S, degrades the active form of coagulation factors V and VIII 
(FVa and FVIIIa) and thereby reduces/inhibits the coagulation process. There are also strong 
specific inhibitors of thrombin, such as antithrombin III (AT III), which also inhibits the 
activated coagulationsfactors IX, X, XI, and XII. 
Fibrinolysis  
Fibrinolysis involves thread dissolution - a series of enzymatic reactions leading to the 
dissolution of fibrin. Fibrinolysis is the most important system for preventing pathological 
coagulation and thrombus formation. The inactive pro-enzyme plasminogen is activated to 
form plasmin. Plasmin degrades both fibrin and fibrinogen into fibrin degradation products 
(FDPs).  Plasminogen is activated by plasminogen activators (PAs), tPA and uPA. 
      tPA is synthesized in the endothelium in both vessels and other tissues. Today tPA is 
made by a recombinant technique and is used for thrombolytic interventions. uPA is mainly 
produced in the kidneys and its effect involves keeping the urinary tract free from clots and 
fibrin precipitates. There is also regulation of the plasminogen activators in the form of two 
plasminogen activator inhibitors (PAI-1and PAI-2). The physiological effect of PAI-1 is to 
moderate the activity of tPA. During pregnancy, the level of PAI-1 is elevated to secure 
optimal hemostasis. Finally, there is a regulation of plasmin by plasmin inhibitors (Figure 2). 
 
Figure 2. Regulation of fibrinolysis. 
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Figure 3 shows a schematic picture of the coagulation system. 
 
Figure 3. The coagulation system.  
4.1.1.2 The hypercoagulable state 
In 1884, the German physician, Rudolf Virchow (1821–1902), postulated a triad of events as 
being  the main causes of VTE, i.e., venous stasis and vessel wall abnormities, such as 
endothelial dysfunction, in combination with hypercoagulability [11]. There are both 
acquired and inherited risk factors for VTE. 
      The acquired risk factors include increasing age, prolonged immobility, major surgery, 
multiple trauma, prior deep vein thrombosis, chronic heart failure, obesity, and malignancy. 
Oral contraceptives and hormone replacement therapy (HRT) increase the risk of VTE. 
The antiphospholipid antibody syndrome and lupus anticoagulans also play an important role 
in the development of VTE.  
      Among the inherited factors that contribute to the overall risk of VTE, mutation of the 
factor V gene (factor V Leiden mutation) constitutes the most prevalent hereditary 
thrombophilia among the white population in Europe. This mutation causes resistance to 
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protein C (APC resistance). Mutation of the prothrombin gene, G20210A, also increases the 
risk of VTE. Furthermore, deficiency of antithrombin (AT, previously referred to as AT-III), 
protein C, and protein S all increase the risk of VTE.  
      Elevated levels of coagulation factors VIII, IX, and XI have been linked to an increased 
thrombotic risk. During the last few decades, some studies have shown that mild to moderate 
hyperhomocysteinemia can be a risk factor for VTE [11]. 
4.2 UPPER EXTREMITY DEEP VEIN THROMBOSIS (UEDVT) 
Primary axillary-subclavian vein thrombosis was first described by Paget in 1875 and by von 
Schrotter in 1884, and it was named the Paget-Schrotter syndrome (PSS)  by Hughes in 1949 
[12]. PSS is most usually seen in the dominant arm of patients who are physically active and 
it can be provoked by excessive overhead activity [13]. PSS is estimated to have an incidence 
of 11 out of 100,000 individuals [14]. 
      Thrombosis of the upper extremity is an uncommon disease with an incidence of 1–11% 
of all DVTs; the figure from different studies varies [15-19].   
      UEDVT can be classified into two groups, primary and secondary UEDVT.  
Primary UEDVT includes idiopathic and effort-related UEDVT and accounts for up to one 
third of all UEDVTs in some studies [20] . Patients with thoracic outlet syndrome (TOS) and 
PSS are also classified as primary.  
      Secondary UEDVT is caused by central venous devices, trauma, and cancer. In large 
cohort studies on patients with UEDVT, the cancer rate is as high as 22–38% [19, 21-24].  
The use of such intravascular devices as central venous catheters (CVCs) [25], peripherally 
inserted central venous catheters (PICCs) [26] , pacemakers [27], and intracardiac 
defibrillators, secondary UEDVT constitutes an increasing clinical problem. Up to 70% of all 
UEDVTs  are diagnosed in association with the use of CVCs [16]. Among 208 intensive care 
patients with CVSs, 33% showed catheter-associated UEDVT [28]. 
      The incidence of primary UEDVT is about 2–11 per 100,000 inhabitants per year [14, 
15]. The low incidence compared with lower extremity deep vein thrombosis (LEDVT) is 
related to both anatomical and physiological differences, such as fewer smaller valves being 
present in the upper limb [29], shorter veins and therefore less surface to form clots on, and 
less immobilization of the arm even in bedridden patients [30]. There is also a higher flow 
rate and less stasis due to gravitational effects in the upper extremity.  
      Increased fibrinolytic activity has been seen in the endothelium of the upper arm, as 
compared to the lower arm [31] and on comparing the upper and lower extremities,  two 
studies have shown a higher fibrinolytic activity in the arms [31, 32].  
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      There is also a difference in some endogenous prothrombotic biomarkers (i.e., thrombin-
antithrombin, antithrombin activity, prothrombin fragments, and p-selectin) when the blood 
sample is taken from the leg veins, compared with blood samples from the antecubital vein, 
which may also contribute to the higher frequency of DVT in the lower limb [33].  
      Risk factors for VTE also differ between UEDVT and LEDVT. Patients with 
noncatheter- associated UEDVT have a less pronounced family history of VTE, compared to 
LEDVT (19% vs. 30%), and are less likely to have undergone major surgery within the last 
30 days [19]. Patients with primary UEDVT also tend to be younger and slenderer [34]. 
      The frequency of coagulation disorders varies: two studies comprising 51 and 31 patients, 
with primary UEDVT have shown rates of 31% and 60%, respectively, for at least one 
coagulation disorder. The most common disorders were antiphospholipid antibodies and 
factor V Leiden mutations [35, 36]. The most important genetic risk factors for VTE are the 
mutation of the genes for FV Leiden mutations and prothrombin G20210A, with incidences 
in cohorts of thrombosis patients of approximately 30% and 10%, respectively [37]. There is 
also evidence from case-control studies that the mutation of the genes for both FV Leiden and 
prothrombin G20210A constitute independent risk factors for UEDVT [21, 38, 39]. 
      Hyperhomocysteinemia has also been discussed as a risk factor for UEDVT, but no 
conclusive results are found in the literature. One interesting finding is that one of the studies 
had a two times higher frequency of coagulation disorders in the subgroup comprising non-
effort UEDVT [36].  
      The use of oral contraceptives is a well-known risk factor for LEDVT, but the association 
does not seem to have the same strength for UEDVT, except for the combination of oral 
contraceptives and mutation of the genes for prothrombin and factor V Leiden [38]. In 
contrast, a study by Vayá et al. [39] reports that the use of oral contraceptives may be 
associated with a six-fold increased risk of suffering from a primary UEDVT. The association 
of primary UEDVT and oral contraceptives requires further investigation,  
4.2.1 Localization of UEDVT and the anatomy of the upper thorax 
The proximal veins of the shoulder and arm, the subclavian and axillary veins, are the most 
usual locations for UEDVT [16, 40, 41].  
      The thoracic outlet region consists of three anatomical spaces: the interscalene triangle, 
the costoclavicular space, and the retropectoralis minor spaces [42]. The subclavian vein re-
enters the chest in front of the anterior scalene muscle, between the clavicle and the first rib 
(Figure 4). The thoracic outlet syndrome (TOS) refers to various forms of compression in the 
thoracic outlet. Compression can be on either nerves or vessels. Compression of both is rare. 
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Underlying venous TOS is mostly asymptomatic prior to thrombosis. Approximately 5–10% 
of cases of TOS are vascular [43]. UEDVT can be caused by venous TOS, with the 
subclavian vein compressed between the clavicle and the first rib.  
 
 
 
 
Figure 4.  Anatomy of the upper thorax and shoulder. 
 
4.2.2 The literature and primary UEDVT 
A recent article by Bleker et al. [44] presents a review of UEDVT. A systematic search of the 
literature was performed in three databases (MEDLINE, EMBASE, and BIOSIS Previews). 
Forty-five studies comprising 4580 patients were included; no randomized studies were 
found. Only 11 studies were prospective and as few as seven had only included primary 
UEDVT. No meta-analysis was performed due to the heterogeneity of the studies and their 
design. We have found very few, and small, studies only including primary UEDVT. 
4.2.3 Recurrences of VTE and mortality  
UEDVT may lead to pulmonary embolism (PE) and the rate ranges approximately from 0 to 
20% (mixed material on both primary and secondary UEDVT) [22, 23, 41, 45-51].  PE is 
more frequent in the lower extremity, up to 50% [2, 3, 7]. The literature states that the 
frequency of PE in primary UEDVT is lower, but further studies are required to find out the 
real frequency. One small study (32 patients) [52] comprising only primary UEDVT showed 
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no pulmonary embolism during the follow-up period of five years.  
      In their review, Bleker et al. [44] reported an average incidence of recurrent VTE in the 
included prospective studies (11 studies and 1661 patients) of 5.1% (range 0–13 %) during a 
follow-up period ranging from 3 to 59 months. The 20 retrospective studies, including 1281 
patients, reported recurrent VTE in 9.8% (range 0–26 %), with follow-ups varying from 3 to 
62 months. The location of the recurrent VTE was in the upper extremity in 78% of the cases 
and 21% were PE. One should remember that this report has included “all sorts of UEDVT” 
(i.e., primary and secondary, including CVC-related UEDVTs). For patients with 
malignancies, the risk of recurrences was two- to three-fold higher, and patients with CVSs 
were highly at risk. 
      Lechner et al. [40] demonstrated, in their study on idiopathic UEDVT, a recurrence rate 
of VTE of  2% (none of them PE). The likelihood of VTE after five years was stated to be 
2% for UEDVT; the same figure for DVT in the lower extremities was 19%.  
      A study by Martinelli et al. on patients with primary UEDVT reported that patients with 
thrombophilia are more likely to have symptomatic recurrences than those without, with 
incidences of 4.4% and 1.6% per year, respectively [38]. 
      There is a striking difference in mortality between primary and secondary UEDVTs. 
Patients with primary UEDVT are typically young and otherwise healthy, whereas subjects 
with secondary UEDVT often suffer from chronic diseases. The Computerized Registry of 
Patients with Venous Thromboembolism (RIETE), an extensive European data registry of 
consecutive patients with VTE mostly from Spain, Italy, and France, shows that the overall 3-
month mortality rate for patients with UEDVT was 11%. The same figure for LEDVT was 
7%. For patients with malignancies, the 3-month mortality rate was as high as 28% [53]. 
In a study from the southern part of Sweden, comprising 63 patients with UEDVT, the 
mortality during a median of 62 (range 31–117) months was at follow-up 24% for all 
UEDVTs, 47% for patients with a malignancy, and 14% for other UEDVT patients [54]. 
4.2.4 Treatment of UEDVT 
There are no randomized studies showing optimal treatment for patients with UEDVT and 
the major clinical guidelines have largely been extrapolated from studies on LEDVT. Current 
international guidelines recommend low molecular weight heparin (LMWH), followed by 
vitamin K antagonist (VKA). The incidence of major bleedings was stated in a review paper 
[44] to be 7.9% for conventional treatment (LMWH and VKA) and 17% for patients 
receiving systemic thrombolysis. The level of bleeding complications is comparable to that of 
the treatment of LEDVT; however, the risk of bleeding is higher for patients with 
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malignancies [55, 56].  
      The role of thrombolysis has been widely debated and the American College of Chest 
Physicians (ACCP) guidelines suggest that it may be beneficial for patients with severe 
symptoms for less than 14 days, good functional status, and a low bleeding risk [57]. Van den 
Houten et al. [58] presented, in their review article from 2016, evidence that catheter-directed 
thrombolysis can be added to the therapeutic arsenal. Another study recommends prompt use 
of catheter-based thrombolytic therapy [59]. However, there are still no randomized studies 
on the subject and no convincing proof that thrombolytic therapy reduces PTS has been found 
[60, 61]. Although there is a high risk of relapse in patients with CVCs, it is not 
recommended to administer prophylactic anticoagulant therapy and recent randomized 
studies did not show any significant benefit [53]. 
      What is the role of surgery and decompression in the treatment of UEDVT? There is also 
no clear answer to this question. Lee et al. presented, in their paper from 2000 (22 patients 
with primary UEDVT), evidence that all patients with primary UEDVT do not need surgical 
intervention. The study suggests a period of observation with anticoagulant therapy before 
surgical intervention to detect the patients in need of decompression [62]. 
4.3 DIAGNOSIS OF VENOUS THROMBOEMBOLISM 
4.3.1 Venous contrast phlebography 
The traditional objective gold standard for diagnosing DVT is based on ascending contrast 
phlebography. The sensitivity is 97% and the specificity 95%, compared to autopsy, for 
LEDVT [63]. Even though phlebography is a diagnostic tool with both high sensitivity and 
specificity, the test is both uncomfortable for the patient and combined with such associated 
risks as allergy to contrast agents, renal problems, and the risk that the contrast agent might 
cause a DVT [64]. Color duplex ultrasonography (CDU) has more and more come to replace 
venous contrast phlebography. 
4.3.2 Color duplex ultrasound (CDU) 
During the last 25 years, the hardware technology has improved the quality of CDU 
dramatically. The method is non-invasive and the risks are negligible. Most laboratories use a 
list of possible duplex findings to diagnose DVT. The first criterion/finding is the inability to 
collapse a vein with the pressure from the probe. A meta-analysis has shown this sign to be 
95% sensitive and 98% specific for, once again, the lower extremity. Regarding the upper 
extremity, CDU is an adequate method [65, 66]. There is, however, an acoustic shadow from 
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the clavicle which limits the visualization of the short segment of the subclavian vein. In 
addition, it might be difficult to visualize the brachiocephalic and/or the superior caval vein. 
4.3.3 D-Dimers 
D-dimers are degradation products that result from the action of plasmin on cross-linked 
fibrin. The use of the blood test has received considerable attention in the past decade. The 
sensitivity and specificity vary from test to test in studies on LEDVT (Table 1) [67-71].  
Table 1. Sensitivity and specificity of different D-dimer tests [67-71]. 
Method  Sensitivity %  Specificity %  
ELISA  96  39  
Red blood cell 
agglutination  
88  64  
Latex agglutination  87  60  
 
The most sensitive test is the ELISA, but it is also the most expensive and time-consuming 
D-dimer test. There are also many other conditions that cause elevated levels of D-dimers, 
such as infection, inflammation, pregnancy, trauma, and post-surgical states.  
D-dimer is usually combined with the Wells score, a widely used clinical decision rule for 
VTE (Table 2). 
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Table 2. The Wells score for the lower extremities. 
Clinical Characteristic Score 
Active cancer 1 
Paralyses, paresis, immobilization 1 
Recently bedridden or major surgery 1 
Localized tenderness of the veins 1 
Entire leg swollen 1 
Calf swelling 1 
Pitting edema 1 
Collateral superficial veins 1 
Previous DVT 1 
Alternative diagnosis at least likely -2 
 
A Wells score of 2 or higher indicates that DVT is likely [71]. 
4.3.4 Magnetic resonance imaging (venography) 
As for CDU, the quality of magnetic resonance imaging (MRI) has improved during the last 
decade. It can be enhanced with contrast agents. Absence of imaging of a vein or an 
intraluminal filling defect indicates the presence of DVT. MRI has a high sensitivity of 97% 
and a specificity of 100% in studies on the lower extremity [72, 73]. The limitations of MRI 
include high cost, lack of portability, and MRI cannot be used on some patients with 
implanted metal devices. MRI has also been shown to be both valuable and usable for 
mapping the anatomy of the upper region of the thorax [74]. 
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4.3.5 Computerized tomographic venography 
Computerized tomographic venography has many of the same advantages as MRI. However, 
it involves the use of ionizing radiation and of intravenous iodinated contrast agent. 
4.4 POSTTHROMBOTIC SYNDROME 
The postthrombotic syndrome (PTS) is a common, chronic, and sometimes severe 
complication of deep venous thrombosis. Twenty to fifty percent of the patients with DVT 
suffer from PTS [75, 76]. Symptoms of PTS are pain, swelling, edema, varicose veins, and 
occasional ulcer formation [77].  The symptoms can be intermittent or persistent and tend to 
improve with resting or elevating the affected limb. PTS is diagnosed on clinical grounds 
based on the patient’s symptoms and signs and is a consequence of venous hypertension, 
reduced muscle perfusion, abnormal microvasculature function, and increased tissue 
permeability [78]. 
      Predictors of a risk for PTS after DVT are older age, high BMI, previous ipsilateral DVT, 
and proximal thrombosis [79]. The best way to prevent PTS is to prevent DVT; therefore, it is 
important to use thromboprophylaxis in patients at risk [80]. The use of compressive 
stockings has been widely discussed, but their utility differs from author to author [80-82]. 
      A significant number of patients with UEDVT experience PTS. The frequency ranges 
from 7% to 46% (weighted mean, 15%) [83] and is, in some studies, as high as 80% [84], but 
the risk of severe PTS seems to be lower than in LEDVT. Interestingly, there seems to be no 
correlation between the degree of PTS and TOS. A small study from 2016 including 21 
patients with primary UEDVT, 10 of which were considered to have TOS-related UEDVT, 
showed the same incidence of PTS whether or not the thrombosis was related to TOS [85]. 
Patients with PTS after UEDVT have a significantly lower quality of life measured with 
VEINES-QOL (see below) [86]. 
4.5 PATIENTS’ PERSPECTIVE REGARDING THE POSTTHROMBOTIC 
SYNDROME 
As mentioned earlier, about 20–50% of the patients with DVT suffer from PTS after two 
years. It is important to measure PTS in a standardized manner and follow its development 
over time. 
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4.5.1 Scales for measuring PTS 
Six clinical scales have been used to define PTS, three of which were developed for chronic 
venous disease in general: the Widmer classification, Clinical Etiology Anatomy 
Pathophysiology (CEAP), and the Venous Clinical Severity Score (VCSS). The other three 
are designed to diagnose PTS after objectively diagnosed DVT: the Brandjes scale, the 
Gingsberg measurement, and the Villalta scale [87].  
-     The Widmer scale classifies the patients into three categories of chronic venous disease 
according to the presence of various clinical signs and five symptoms reported by the patient 
(pain, heaviness, heat, tension, and tiredness of the limb) [88].  
-     The CEAP categorizes patients into eight classes of increasing severity with modifiers 
that reflect the underlying etiology (congenital, primary, or secondary DVT), the anatomic 
distribution, such as superficial, deep, or perforating veins, and pathophysiologic conditions – 
obstruction and/or reflux [89]. 
-     The VCSS includes elements of CEAP and other criteria (number, size, and duration of 
ulcers, use of compression therapy, and only a single symptom, pain) [90]. 
-     The Brandjes scale uses separate subscales to determine whether or not patients have no, 
mild to moderate, or severe PTS, including items concerning symptoms, signs, and 
differences in calf circumference [91].  
-     The Ginsberg scale diagnoses PTS if the patient reports daily leg pain and swelling with 
duration of at least one month that occurs 6 months or more after the acute DVT and is made 
worse by standing/walking and relived by rest or leg elevation. The patient reports whether 
the symptoms have improved or not since the last assessment. This is a way of attempting to 
objectify the course of PTS [81]. 
      In addition, there are two scales which have been used by some authors, VEINES-SYM 
and VEINES-QOL, originally designed for the lower extremity and modified for the upper 
extremities by replacing the designation “leg” with “arm” [92]. The scales reflect both the 
patients’ subjective symptoms from the affected limb and how these symptoms affect the 
activities of daily living [93]. 
4.5.2 The Villalta postthrombotic scale 
As described above, a number of clinical scales have been used for measuring PTS. The 
Standardization Committee of the International Society on Thrombosis and Haemostasis 
nowadays recommends the Villalta scale. This scale consists of both the patient’s subjective 
symptoms and signs found by the clinician (Table 3). The Villalta scale gives a validated 
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score for assessing PTS [94] in the lower limb and correlates with such quality of life scores 
as generic disease-specific quality of life (SF-36) [95]. 
Table 3. Villalta PTS scale. 
Symptoms and clinical 
signs  
None  Mild  Moderate  Severe  
Symptoms   
Pain  0  1  2  3  
Cramps  0  1  2  3  
Heaviness  0  1  2  3  
Paresthesia  0  1  2  3  
Pruritus  0  1  2  3  
Clinical signs   
Pretibial edema  0  1  2  3  
Skin induration  0  1  2  3  
Hyperpigmentation  0  1  2  3  
Redness  0  1  2  3  
Venous ectasia  0  1  2  3  
Pain on calf 
compression  
0  1  2  3  
Venous ulcer  0  1    
 
A total score of 5 or higher is classified as the presence of PTS and a score of 15 or higher is 
classified as severe PTS. For upper extremity deep vein thrombosis, several studies have used 
a modified Villalta scale to diagnose and classify the severity of PTS [83]. This scale has not 
been validated for the arm, but there is no other validated scale available. 
4.5.3 Disability of the arm, shoulder, and hand questionnaire 
The disability of the arm, shoulder, and hand (DASH) questionnaire is a validated, 
standardized, self-administered questionnaire that assesses symptoms and disabilities of the 
upper extremities by measuring “global” disability from 0 (absent) to 100 (severe). Examples 
of questions asked concern opening a tight or new jar, writing, doing gardening, making a 
bed, etc. Answers are given on a five-degree scale ranging from “No difficulty” to “Unable” 
[96]. 
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4.5.4 Visual analog scale 
The visual analog scale (VAS) is a psychometric response scale that can be used 
in questionnaires. It is a measuring instrument for subjective characteristics or attitudes that 
cannot be directly measured. When responding to a VAS item, the respondents specify their 
level of agreement with a statement by indicating a position along a continuous line between 
two endpoints. In this thesis, VAS was used to estimate pain and disability.  
4.6 METHODS FOR ASSESSING VENOUS FUNCTION 
4.6.1 Color duplex ultrasound (CDU) 
During the past decade, color duplex ultrasound has become the first line of diagnostics for 
DVT. It is also used to detect chronic venous disease (CVD), including postthrombotic 
changes in the vessels. The detectable changes are persistent obstruction of the vessel and 
wall abnormalities, such as wall thickening, reduced lumen, and reduced compressibility [97]. 
By the use of pulsed Doppler and color flow, the technique also provides information of 
venous flow and venous reflux [98]. 
4.6.2 Plethysmography 
Venous plethysmography records volume changes in a tissue segment in order to assess 
venous function. During the 1990s, there began to be less use of plethysmography due to 
the increasing use of CDU. Plethysmography has been used mostly for examination of the 
lower limb but there are studies that have used plethysmography for examination of the 
upper extremity [84, 99]. 
 .    
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5 AIM OF THE PRESENT THESIS 
 
The overall aim of this thesis was to increase the existing knowledge of primary UEDVT and, 
by means of this knowledge, be able to treat future patients more adequately, based on 
science and proven experience. 
The specific aims were: 
• To evaluate venous function, late sequelae and PTS in patients with primary UEDVT; 
• To identify risk factors for primary UEDVT; 
• To find out the level of recurrences; 
• To investigate the anatomy of the thoracic outlet in the closeness of the subclavian 
vein; 
• To correlate objective measurements with the patients’ subjective symptoms;  
• To quantify the comorbidity of patients with primary UEDVT. 
5.1 PAPER I 
This study was performed to describe venous function, residual morphologic abnormalities, 
and the occurrence of PTS in patients with conservatively treated primary UEDVT. In 
addition, the aim was to correlate PTS with color duplex ultrasound and plethysmography.  
5.2 PAPER II 
The aim of this paper was to examine patients with primary UEDVT with respect to 
underlying thrombophilic disorders, postthrombotic symptoms, and the rate of complications 
and recurrences. 
5.3 PAPER III 
The primary objective of this study was to examine the anatomy of the subclavian region in 
patients with primary UEDVT with a focus on structural findings that may interfere with the 
function of the vessel. The secondary objective was to investigate whether there were any 
correlations between the area of the subclavian vein or costoclavicular distance and 
symptoms of PTS measured by three different clinical methods (i.e., the Villalta post 
thrombotic score, DASH, and VAS). 
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5.4 PAPER IV 
Most studies on UEDVT are on mixed material including patients with both primary and 
secondary UEDVT. Comorbidity is well-described in patients with secondary UEDVT, but 
we have not found any studies that describe the comorbidity for primary UEDVT. 
The aim of this case-control study was to compare comorbidity in patients with primary 
UEDVT with that of a control group. 
6 ETHICS 
All studies were approved by the Regional Ethical Review Board in Stockholm and all 
patients and controls provided their written informed consent (Papers I–III) before inclusion 
in the studies. 
7 STATISTICS 
7.1  PAPER I 
Data are presented as means and 95% confidence intervals. Differences in the means were 
tested for statistical significance using two-sided paired or unpaired Student’s t tests. 
Pearson’s or Spearman’s correlation analyses were used to explore relationships between 
different variables. Differences between proportions were analyzed using χ2 tests. Statistical 
significance was set at P <0.05. 
7.2 PAPER II 
Differences in median were tested for statistical significance with the Mann-Whitney U test 
and the Bonferroni correction was performed. Statistical significance was set at P <0.05. 
Spearman´s correlation was used to study the relationship between the DASH and Villalta 
scores. 
7.3 PAPER III 
A nonparametric test was used because it was difficult to evaluate the distributional 
assumption due to the relatively small number of observations. Differences between patients 
and controls were tested using the Mann-Whitney U test. The Wilcoxon signed rank test was 
used when testing differences within the patient group. Correlation was tested with 
Spearman´s rank correlation. P <0.05 represented a significant difference. 
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7.4 PAPER IV 
Differences in proportions between cases and controls were tested with Fisher's exact test.  
Differences in the means of healthcare contacts were tested with an independent t test. All 
tests were two- sided and a P value of <0.05 was considered to be statistically significant.  
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8 MATERIAL AND METHODS 
8.1 PAPER I 
8.1.1 Patients 
A retrospective search of medical records from Södersjukhuset and Karolinska University 
Hospital for the years 1992–2002 identified 563 patients diagnosed with UEDVT. All 
medical records were analyzed according to the underlying disorders and risk factors for 
UEDVT. Patients with central venous catheters, pacemaker devices, and known malignant 
disease were excluded from the study and 37 patients were identified with a previous primary 
UEDVT. Thirty-two patients (23 females, 9 males) agreed to participate in the study (one 
patient treated with thrombolysis was excluded from paper I but participated in paper II) 
(Figure 5).  
 
 
Figure 5.  Flow chart for patients included in Papers I–III. 
Thirty patients (94%) were diagnosed objectively by contrast venography; 11 of these 
patients (34%) also had the thrombosis confirmed by CDU and one patient had a 
computerized tomography for diagnoses. Two patients were diagnosed by CDU only. The 
localization of the thrombosis was 66% solely in the subclavian vein, 22% in both subclavian 
and axillary veins, 6% in the subclavian, axillary, and brachial veins, and 6% in the brachial 
vein alone. In eight (25%) of the patients, the thrombosis also involved the basilic vein. 
      All patients were treated with LMWH and VKA therapy for 3–6 months. One patient 
received thrombolysis. All but six patients were investigated with chest X-ray or 
computerized tomography (CT) to exclude an extra cervical rib; none of the investigated 
563 
UEDVT 
526 secondary 
UEDVT 
37 primary 
UEDVT 
32 agreed 
15 agreed   
Paper III (MRI) 
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patients had an extra cervical rib. Six of the UEDVTs were considered to be effort-related 
according to the medical records, i.e., they had a history of vigorous or unusual exercise 
within seven days prior to the diagnosis: One patient had carried a heavy bag, two patients 
had recently started an exercise regimen, one patient had removed old wallpaper, one patient 
had been working with a drilling machine with elevated arms, and one had worked rigorously 
shoveling sand in a garden.  
      The main characteristics of the patients are shown in Table 4. The mean patient age was 
45 years at inclusion (range, 21–84) and 23 (71%) were women. The age at diagnosis were 39 
years (median) and 40.7 years (mean), (range, 17–77).  
Table 4.  Main clinical characteristics of the patients included in Studies I–II 
Characteristics    
Male/female, n 9*/23 
Median age at thrombosis, y (range)  39 (17–77)  
Mean age at thrombosis , y (range) 40.7 (17-77) 
Positive family history of DVT, n (%)  7 (22)  
Smokers, n (%)  6 (28)  
Use of oral contraceptives or HRT**, n (%, female)  12 (52)  
Right arm, n (%)  16 (50)  
Dominant arm, n (%)  15 (47)  
Effort-related, n (%)  6 (19)  
* 8 male in paper I 
** Hormone replacement therapy 
8.1.2 Methods 
All patients were interviewed and examined clinically and the circumference of both arms 
was measured. This was performed with the patient sitting with the arms in a hanging 
position, with measurement of the circumference of the forearm and the upper arm 12 cm 
beneath and above the elbow.  
      Due to the fact that there is no objective “gold standard” test to diagnose PTS after 
UEDVT, we used a modified form of the Villalta scale. The patients were asked to rate the 
severity of each of the five symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and 
the physician evaluated each of the six signs (edema, prominent veins on the arm, prominent 
veins on the shoulder or anterior chest wall, redness, tenderness, dependent cyanosis) on a 
scale of 0 (absent) to 3 (severe). A score of 5 or higher was classified as the presence of PTS 
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and a score of 15 or higher as severe PTS. 
      Duplex scanning was performed by a technician with >10 years of experience using the 
color duplex technique to diagnose DVT.  In each patient, the radial, ulnar, brachial, cephalic, 
basilic, axillary, subclavian, and internal jugular venous segments were evaluated. The 
occurrence of vessel wall abnormalities, such as wall thickening and a reduced or occluded 
lumen, was observed, as well as flow in prominent collateral veins, compressibility, and 
blood flow patterns, to identify postthrombotic changes. Valvular function was evaluated and 
a reflux duration of >0.5 sec was considered significant. 
 The duplex findings were classified into four categories: 
1. Normal findings. 
2. Mild changes – patent veins with slight wall thickening, almost compressible, normal 
spontaneous blood flow and some dilated collateral veins. 
3. Moderate to severe changes – patent veins with a reduced lumen because of a residual 
thrombus, decreased compressibility, and dilated collateral veins. 
4. Occluded – residual thrombus with occlusion of the lumen, uncompressible lumen, 
absence of color flow, and blood flow in several prominent dilated collateral veins. 
In this thesis, we used a computerized strain-gauge technique modified for the arm to assess 
venous function [100]. When performing the plethysmography of the upper limb the patient 
was sitting on a chair and resting the arms on an arm support. Inflatable cuffs were wrapped 
around the arms and strain-gauge wires were placed on each forearm (Figure 6). 
 
 
Figure 6. Setup for plethysmography. 
 
Venous occlusion is established by a pressure of 60 mm Hg within the cuffs. To detect 
when the plateau of the filling phase was reached, we used a capacitance mode which 
detects when the venous filling is less than 0.1 mL per 100 mL over 20 sec. When the 
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volume curve plateau is established in both arms the cuff pressure is rapidly released, 
allowing outflow of the accumulated blood and a fall in the volume curve (Figure 7).  
 
 
Figure 7.  Schematic presentation of the volume curve. 
- Venous volume (VV, mL per 100 mL) is the maximum volume change during the 
occlusion phase. 
- Venous emptying (VE, mL per 100 mL per min) describes the outflow rate during 
the first second after deflation. 
- EV4/VV shows the volume of blood expelled during the initial 4 sec, divided by the 
maximum VV. 
The mean of two determinations was used for each variable. 
8.2 PAPER II 
8.2.1 Patients 
The same patients included in Paper I, plus the one who received thrombolysis, were 
interviewed with a focus on risk factor diagnostics and treatment. 
8.2.2 Methods 
The modified Villalta score was used to quantify PTS and the DASH test to assess symptoms 
and disability of the upper extremity.  
      To evaluate the working capacity of the upper extremities, an arm exercise tests was used 
[101] with an increasing work load of 10 W every minute. The test was discontinued when 
the patient perceived subjectively experienced exhaustion. The test was performed on an 
electrodynamically braked bicycle ergometer (Rodby 830, Rodby Innovation AB, Hagby, 
Sweden) adapted for arm exercise (Figure 8). 
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Figure 8 Setup for arm exercise capacity test. 
The circumference of the upper arm and forearm were measured in both arms, before and 
after exercise. In addition, VAS was used to estimate pain and disability. 
      Blood samples for the following coagulation factors were taken at diagnosis and/or 
inclusion in the study: mutation of factor V Leiden, deficiency of protein C and protein S-
free, antithrombin, antiphospholipid antibodies, and homocysteine. 
Levels of fibrinogen and von Willebrand factor were analyzed at inclusion. 
8.3 PAPER III 
8.3.1 Patients 
The same patients as in Papers I and II were asked to participate in this follow-up study. 
Fifteen patients, 5 males and 10 females agreed to participate. The major reasons for refusing 
participation were the use of MRI, contrast agent, and a lack of time and interest. The patients 
had no concomitant diseases, no previous central venous catheters, and they had all been 
investigated with a CT scan of the thorax at the index event to exclude cancer-related 
thrombosis or an extra cervical rib. All UEDVTs were localized in the subclavian vein. Ten 
patients had their UEDVT in the left arm; only five patients had it in the dominant arm.  
All primary events were diagnosed by phlebography. The mean time from the thrombotic 
event to the MRI was 6.9 years (range, 3.6–11.3 years). 
      A control group of 15 healthy persons without previous UEDVT, matched according to 
sex, age, and body mass index (BMI), was used. The group was enrolled on a voluntary basis 
(Table 5). 
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Table 5. Characteristics of patients and controls included in the study. 
Characteristics      Patients   Controls  
Male/female, n 5/10  5/10  
Smokers, n (%)  3 (20)  1 (7)  
Mean age at MRT, y (range)  51 (42–66)  53 (42–70)  
Median age at MRT, y, (range) 47 (42-66) 50 (42-70) 
Weight, kg, median (range)  69 (56–115)  72 (58–102)  
Height, m, median (range)  1.74 (1.62–1.90)  1.72 (1.48–1.88)  
BMI, median (range)  24.9 (20.6–31.9)  24.5 (22.6–32.2)  
Ethnic origin  All Scandinavian  All Scandinavian  
 
8.3.2 Methods 
In the third paper, MRI was used to detect remaining chances such as reduced vessel area or 
total occlusion of the subclavian vein after UEDVT. In addition, the anatomic structures of 
the thoracic outlet were visualized. MR imaging was performed on both patients and controls 
and enhanced by a blood pool contrast agent (10 ml Gadofosveset, 0.25 mmol/mL 
Vasovist®). Two sets of sequences were preformed; the first set of sequences was performed 
with the arms alongside the body and the second with the arms over the head (hyper-
abduction to 120° and external rotation). 
      The images were analyzed for patency and prevalence of stenosis/occlusion of the 
subclavian vein and measurements of the costoclavicular space.  
      The costoclavicular space was measured using a sagittal view. The image in which the 
first rib was seen with its longest portion was used to measure the costoclavicular distance. 
The shortest distance between the dorsal portion of the clavicular cortex and the ventral 
delineation of the cortex of the first rib was measured. The values obtained were derived as a 
consensus between two observers. All measurements were performed in both positions of the 
arms. In addition, the width of the subclavian vein was evaluated by means of vessel lumen 
area measurements in the costoclavicular space. In cases of postthrombotic occlusion (2 
patients) and a nondetectable vessel (1 patient), no area measurement was performed; thus, 
vessel area was calculated for 12 patients. 
      Postthrombotic syndrome and disability of the upper extremity were once again 
quantified by two tests: the modified Villalta score and DASH; VAS was also used to 
quantify pain. 
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8.4 PAPER IV 
8.4.1 National Patient Register 
In Sweden, there is a unique possibility of following patients nationally over the years. The 
National Patient Register (NPR) has collected data on inpatients at public hospitals (the vast 
majority of hospitals) since 1987 and from 2001 also on outpatient visits, in both public and 
private healthcare. In combination with the personal registration number (PRN), it is possible 
to extract data from the NPR even for rare diseases. 
8.4.2 Patients 
Both in- and outpatients in the NPR who might have had an upper extremity deep vein 
thrombosis during the years 2001–2011 were traced with the following ICD-10 codes for the 
diagnoses:  
- I80.8 Phlebitis and thrombophlebitis of other sites,  
- I80.9 Phlebitis and thrombophlebitis of an unspecified site,  
- I82.8 Embolism and thrombosis of other specified veins and,  
- I82.9 Embolism and thrombosis of an unspecified vein. 
From these data, we identified patients 18 years of age or older. Patients diagnosed with 
cancer, orthopedic procedures on the shoulder and upper arm, and devices in the vessel 
within a period of two years before the index point (the first time any of the above DVT 
codes were registered in the NPR) were excluded in both case and control groups. We 
assumed that the majority of all important events that could influence the subclavian area 
were normalized after two years. Therefore, the first index point for inclusion was after 2002. 
To get a follow-up period of a minimum of three years, only patients with their first 
thrombotic event reported in the NPR before 2009 were included. Thus, the inclusion period 
is from the beginning of 2003 to the end of 2008. For patients with more than one thrombotic 
event, the first one was considered to be the index point. 
      Unfortunately, there is no exclusive code in the ICD-10 for upper extremity thrombosis. 
Our hope was that, by choosing the above ICD codes, we would find a great match between 
ICD-codes reported in the NPR and the presence of UEDVT, but, unfortunately, this was not 
the case. To validate the register data, 600 patients were randomly selected from a total of 
46,349 individuals with thromboembolisms, using the random number generator in IBM 
SPSS. Their medical records were ordered for review and 520 were handed over. We found 
25 cases (5%) with primary upper extremity deep vein thrombosis, all treated with LMWH 
and VKA; none of the cases involved initial thrombolysis.   
 28 
8.4.3 The control group 
A critical characteristic of subject selection in cohort studies is to have both the exposed and 
unexposed groups selected from the same source population. In order to have comparable 
groups, we selected patients with appendicitis as the comparison group. Patients with 
appendicitis are perceived to reflect the same exposure pattern as the general population, and 
appendectomy is not related to the causal pathway for the development of UEDVT or any 
other disease. Therefore, we minimize the risk of bias and confounding 
      Patients from the NPR with appendicitis were included for the same periods of time as for 
patients with UEDVT. The following ICD-10 codes were used:  
 
- K35.0 Acute appendicitis with generalized peritonitis,  
- K35.1 Acute appendicitis with peritoneal abscess,  
- K35.2 Acute appendicitis with generalized peritonitis,  
- K35.3 Acute appendicitis with localized peritonitis,  
- K35.8 Acute appendicitis, other, and unspecified,  
- K35.9 Acute appendicitis, unspecified,  
- K36.9 Other appendicitis,  
- K37.9 Unspecified appendicitis. 
The first time some of these ICD codes were reported in the NPR was considered to be the 
index point. Ten percent of the controls had more than one registration regarding appendicitis 
and, for them, the last registration was classified as the index point. These registrations were 
adjacent in time (less than five days) and were therefore interpreted to be for the same disease 
episode. For appendicitis, there are specific ICD codes and therefore there was no need for a 
review of the medical records. 
      The 25 cases were matched, on an individual basis, with 474 controls who were randomly 
selected from the individuals who were identical with the cases according to sex, their age at 
the index point, and the year of the index point. By so doing, the groups were also made 
comparable for the observation period, the time from the index point to the end of the year 
2011.  
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8.4.4 Comorbidity and healthcare contacts 
Comorbidity was described as the number of unique ICD codes (diagnoses) registered in the 
NPR in each ICD group for cases and controls from the index point to the end of the year 
2011. For a better overview, some ICD chapters were merged into study-specific ICD groups 
(Table 6).  The number of healthcare contacts was recorded as the number of admissions to 
hospital or outpatient visits. 
 
Table 6 . ICD chapters and study-specific ICD groups.  
 
 
ICD group 
(study-specific) 
  ICD code 
I 1 Certain infectious and parasitic diseases A00-B99 
II 2 Neoplasms  C00-D48 
III 3 Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism  
D50-D89 
IV 4 Endocrine, nutritional, and metabolic diseases E00-E90 
V 5 Mental and behavioral disorders  F00-F99 
VI 6 Diseases of the nervous system  G00-G99 
VII–VIII 7 Diseases of the eye and adnexa 
 Diseases of the ear and mastoid process  
H00-H59 
H60-H95 
IX 8 Diseases of the circulatory system I00-I99 
X 9 Diseases of the respiratory system J00-J99 
XI 10 Diseases of the digestive system K00-K93 
XII 11 Diseases of the skin and subcutaneous tissue L00-L99 
XIII 12 Diseases of the musculoskeletal system and connective 
tissue   
M00-M99 
XIV 13 Diseases of the genitourinary system N00-N99 
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XV 14 Pregnancy, childbirth and the puerperium O00-O99 
XVI 15 Certain conditions originating in the perinatal period P00-P96  
XVII 16 Congenital malformations, deformations, and chromosomal 
abnormalities 
Q00-Q99 
XVIII- 
XXII 
17 Symptoms, signs, and abnormal clinical and laboratory 
findings, not elsewhere classified 
Injury, poisoning and certain other consequences of external 
causes 
 
External causes of morbidity and mortality 
Factors influencing health status and contact with health 
services 
Codes for special purposes 
R00-R99 
 
S00-S99 
T00-T98 
V01-V99 
W00-Z99 
U00-U49 
U82-U85 
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9 RESULTS 
9.1 PAPER I 
This study was performed to describe venous function, residual morphologic abnormalities, 
and the occurrence of the postthrombotic syndrome in patients with conservatively treated 
primary upper-extremity deep venous thrombosis and, in addition, to correlate PTS with 
color duplex ultrasound and plethysmography. 
9.1.1 Clinical examination and interview 
The patients reported swelling and tension in the thrombotic arm in 71 % (22 patients) 
especially during and after heavy exercise. Thirty-two percent (10 patients) also reported 
reduced strength and pain; in addition, they reported distension of the superficial veins and a 
different skin color. None of the patients had any symptoms in the contralateral arm. 
      On measuring the circumference of the arm, there was only a significant difference for the 
upper arm (Table 7). 
Table 7. Circumference of the arms. 
 Thrombotic arm (mean, 
cm) 
Nonthrombotic arm 
(mean, cm) 
Difference 
(mean, cm) 
P value 
Upper arm 30 (24–26) 29 (23–26) 0.9 P <.001 
Lower 
arm 
24 (20–31) 24 (19–31) 0.2 ns 
 
Postthrombotic scores ranged from 1 to 9 (median, 3). Twenty-two patients (71%) were 
classified as having no or minimal PTS (score < 5). The remaining nine patients had mild to 
moderate PTS (score 5 to 9). Thus, none of the patients had severe PTS (score ≥15). 
9.1.2 Color duplex ultrasound 
The duplex findings were classified, as described, into four categories. Eight patients (26%) 
had normal findings, 5 (16%) had mild changes, 14 (45%) were classified as having 
moderate-to-severe changes, and 4 (13%) still had an occluded deep venous segment. 
Eighteen patients (58%) had residual thrombi (Figure 9).  
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Figure 9. Color Doppler image of the subclavian vein just below the clavicle showing a residual thrombus 
(arrow) with flow in a partially recanalized lumen. 
The study did not show any significant association between the PTS score and duplex 
findings (category 1 to 4, Spearman’s r = 0.22).   
9.1.3 Computerized strain-gauge plethysmography 
The venous emptying, venous volume, and EV4/V were all significantly lower in the arms 
with a previous DVT than in the contralateral arms (P <0.001). Thirty-five percent of the 
thrombotic arms had a VE below the lower normal limit of 68 mL/100 mL per min. The 
lower limit was defined in a previous study by our group as the mean of VE -2SD [102]. 
Figure 10 shows plethysmographic curves from a patient with a significant outflow 
obstruction after a right-sided upper-extremity deep vein thrombosis.  
  
 
 
 
 
  33 
 
Figure10. Example of plethysmographic curves from a patient with a significant outflow 
obstruction after a right-sided upper-extremity deep vein thrombosis.  
There was no significant association between plethysmographic and duplex findings, but 
there was a progressive reduction in venous emptying for each increase in the 
ultrasonographic degree of postthrombotic changes in the vessel. Patients with PTS generally 
had lower venous emptying and venous volume values than those without PTS, but these 
differences were not statistically significant.  
In Summary 
Forty-two percent of the patients had normal or mild changes in the ultrasonography, 71% 
were classified as having none or mild PTS. Plethysmography showed reduced venous 
emptying in the thrombotic arm. There was no significant association between color duplex 
findings and PTS or between plethysmography and PTS. 
9.2 PAPER II 
The aim of this study was to examine patients with primary UEDVT with respect to 
underlying thrombophilic disorders, postthrombotic symptoms, rate of complications, and 
recurrences. 
9.2.1 Coagulation disorder 
The prevalence of thrombophilia in our study population was 40% (Table 8), similar to that 
for LEDVT. Mutation of the gene for factor V Leiden and elevated fibrinogen were the most 
common coagulation abnormalities. Note that fibrinogen was analyzed without any signs of 
inflammation for at least two years after the thrombotic event, including one patient with a 
rheumatic disease. One out of six patients with a factor V mutation was homozygous. A 
young male, 17 years old, had three different coagulation disorders (deficiency of proteins C 
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and S and a heterozygote mutation for factor V) without any positive family history. In three 
patients, there was a slight increase in the D-dimer level at follow-up (0.6–1.13.4 mg/L). Five 
patients on HRT or oral contraceptives had thrombophilia consisting of one mutation of 
factor V Leiden and four patients with a slight increase in fibrinogen. 
Table 8. Prevalence of thrombophilic abnormalities in the study population, compared to the general population 
and unselected patients with DVT in the lower limb [11, 103]. 
Thrombophilic abnormality  Study group  
n (%)  
General  
Population  
%  
  DVT in the lower limb  
% 
Factor V Leiden mutation  6/32 (19)  3.6-6.0    21.0 
Antiphospholipid antibodies  1/32 (3)  1-5     
Protein C deficiency  1/31 (3)  0.14-0.5    3.2 
Protein S deficiency  1/28 (4)  0.16-0.21    2.2  
Hyperhomocysteinemia  0/32      
Antithrombin deficiency  1/32 (3)  0.02-0.17    1.1  
Elevated vWF antigen  0/32       
Elevated D-dimer  1/32 (3)       
Elevated fibrinogen  7/31 (22)*     
*Range 4.0–5.2 (normal range, 2.0–4.0) 
9.2.2 Villalta postthrombotic score, DASH, VAS, and working capacity 
The two questionnaires (modified Villalta and DASH) showed a median value for the 
modified Villalta score of 3 (range 1–9) and, for DASH, a median value of 6 (range 0–63). 
Nine patients (28%) were defined as having PTS;  the cut-off level for defining PTS is >5 
[104] .   
      On the visual analog scale (VAS), the patients estimated remaining pain and disability. 
The median values were 7 (range 0–95, mean 18) for pain and 9 (range 0–80, mean 20) for 
disability. No correlation was found between pain and disability or between pain and 
disability and DASH. 
      On comparing the results from the two questionnaires DASH and the modified Villalta 
score, we found a correlation between the two tests (r = 0.58, P <0.001) (Figure 11).  
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Figure 11. Correlation between Villalta score and DASH. 
The patients were divided into two groups with or without PTS according to Table 9. 
The PTS group had significantly higher DASH scores than the non-PTS group (P = 0.03). 
There was no difference between the two groups according to VAS for pain or disability. 
      Arm exercise capacity had a median value of 70 W (range, 40–160 W). There was no 
significant difference in the increase of the arm circumference after the arm exercise test in 
any of the arms (Table 9). All patients showed increased redness and more prominent veins in 
the thrombotic arm after the arm exercise test. 
Table 9. Functional disability (DASH), increase in arm circumference after exercise, arm exercise capacity test, 
pain and disability measured by VAS in patients with and without postthrombotic syndrome. 
Measure  PTS* 
(n = 9)  
No PTS† 
(n = 23)  
P 
value  
DASH, median 25 (range, 4.2–63.3) 4.2 (range, 0–60) 0.033 
Increased circumference, median  
(cm)  
1 (range, 0–1.5)  0.5 (range, 0–2)  ns  
Arm exercise capacity , median (W)  70 (range, 40–110)  70 (range, 50–160  ns  
VAS pain (median)  28.5 (range, 3–95)  7 (range, 0–40)  ns  
VAS disability (median)  23 (range, 2–56)  7 (range, 0–80)  ns  
* Villalta score >4, †Villalta score <4. 
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9.2.3 Recurrences 
None of the patients developed malignancy, pulmonary embolism, or recurrent DVT during 
the period from diagnosis to inclusion in the study, mean period, 5 years (range, 2–9 years). 
In summary, this study supports the view that primary UEDVT is a benign disorder, with a 
high frequency of PTS (28%), but with a low risk of recurrence. The overall frequency of 
coagulation disorders was 40%, which is lower than earlier reported. 
9.3 PAPER III 
The primary objective of this study was to examine the anatomy of the subclavian region in 
patients with primary UEDVT with the focus on structural findings that may interfere with 
the function of the vessel. The secondary objective was to investigate whether or not there 
was any correlation between the area of the subclavian vein or costoclavicular distance and 
symptoms of PTS measured by three different clinical methods (i.e., the Villalta post- 
thrombotic score, DASH, and VAS). 
9.3.1 Costoclavicular distance 
The costoclavicular distance in the right and left arms was significantly narrower in the 
UEDVT patients than in controls when the arms were held alongside the body and in a hyper- 
abduction/external rotation position of only the left arm (Table 10).  
Table 10. Median values, (range) and P values for differences in measurements (mm) of the costoclavicular 
distance between patients and controls. 
 Alongside  Hyperabduction/external 
rotation  
 Patients  Controls  P value  Patients  Controls  P value  
 Right arm  Right arm  
Costoclavicular distance  12.0 
(4.0–14.0)  
18.0 
(8.8–26.9)  
<0.001*  5.0  
(3.1–12.0)  
7.8 
(3.5–16.1)  
0.051  
 Left arm  Left arm  
Costoclavicular distance   9.0  
(6.0–14.0)  
16.6 
 (7.8–28.2)  
0.001*  5.0  
(3.0–11.0)  
8.1  
(3.5–16.8)  
0.04*  
* P values of <0.05 represent a significant difference.  
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On comparing the patients’ thrombotic and non-thrombotic arms, there was a significant 
difference with the arms held alongside the body, but not in the supine position (Table 11). 
Table 11. Median values (range) and P values for differences in measurements of the costoclavicular distance 
(mm) between nonthrombotic and thrombotic arms in patients. 
 Alongside    Hyperabduction/ext. rotation    
 Non-thrombotic 
arm  
Thrombotic 
arm  
P value  Non- 
thrombotic  
arm   
Thrombotic 
arm  
P 
value   
Costoclavicular 
distance   
11.0 
(6–14)  
9.0  
(4–14)  
0.049*  5.0 
(3–12)  
5.0 
(3–11)  
0.35   
* P values of <0.05 represent a significant difference.   
 
9.3.2 Area of the subclavian vein 
Three patients were excluded after measuring the area of the subclavian vein due to total 
occlusion (2 patients) and one patient had a nondetectable vein. There was a significant 
difference in the vessel area between the thrombotic and nonthrombotic arms in patients in 
both positions. Ten out of the 12 patients had total compression with no bloodflow in the 
vessel in the thrombotic arm with the arm held in a hyperabducted and externally rotated 
position.  
Table 12. Median values (range) and P values for differences in measurements of vessel area (mm
2
) between 
nonthrombotic and thrombotic arms in patients. 
 Alongside    Hyperabduction/ext. rotation    
 Non-thrombotic 
arm  
Thrombotic 
arm  
P 
value  
Non-thrombotic 
arm   
 Thrombotic 
arm  
P value   
Area of v. 
subclavia  
64.5  
(41–112)  
24.5  
(0–47)  
0.005*     9.0  
 (0–21)  
0.0 
(0–6)  
0.007*   
* P value of <0.05 represents a significant difference.   
. 
Regarding the area of the vein between the non-thrombotic arm in patients and controls there 
was no significant difference when the arms were alongside the body. However, in the 
position with the arms raised over the head, there was a significant difference between the 
two groups (Table 13). 
 
 38 
Table 13. Median values (range) and P values for differences in measurements of vessel area (mm
2
) between 
the nonthrombotic arm of patients and that of controls. 
 Alongside  Hyperabduction/external rotation  
 Patient  Controls  P value  Patient  Controls  P value  
 Non-thrombotic 
arm  
Right arm   Non-thrombotic 
arm  
Right arm   
Area of v. 
subclavia   
64.5 
(41–112)  
76.0  
(13–128)  
0.58  9.0 
(0–21)  
23.0  
(0–88)  
0.008*  
 Non-thrombotic 
arm  
Left arm   Non-thrombotic 
arm  
Left arm   
Area of v. 
subclavia   
64.5  
(41–112)  
65.0 
(43–118)  
0.79  9.0  
(0–21)  
31.5 
 (0–67)  
0.002*  
*P values of <0.05 represent a significant difference. 
. 
9.3.3 Villalta postthrombotic score, DASH, and VAS 
Eleven patients out of the 15 presented no signs of PTS, four patients showed PTS, two of 
which had severe PTS according to the modified Villalta test. The mean values for DASH 
and VAS for pain were 30.4 (0–85) and 44.8 (0–92), respectively. The patients presented 
almost identical results individually, compared with the previous questionnaire two years 
earlier, indicating that the symptoms were consistent over the observation period. 
      There was a high correlation between DASH, the Villalta score, and VAS (Table 14), but 
no correlation between either the costoclavicular distance or the area of the subclavian vein 
and the patients’ symptoms measured by VAS, the Villalta score, or DASH. 
Table 14. Correlation between DASH, VAS, and Villalta score. 
  Correlation  
DASH  Villalta score  R = 0.925  
DASH  VAS  R = 0.951  
Villalta score  VAS  R = 0.975  
 
In summary, this study may indicate that there is a relationship between anatomical 
conditions of the thoracic outlet (i.e., distance from the clavicle to the first rib) and the 
development of primary UEDVT, both effort-related and idiopathic. Another finding is that 
there seems to be a low correlation between the degree of obstruction, measured as the area 
of the subclavian vein and the costoclavicular distance, and PTS. 
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9.4 PAPER IV 
The aim of this case-control study was to compare comorbidity in patients with primary 
UEDVT with that of a control group. 
The 25 cases and 474 controls, 48% males and 52% females, had, at the index point, a mean 
age of 48 years (range, 20–80; SD, 17.5). The women were slightly older. The mean followup 
time was 8 years (range, 5.7–9). 
9.4.1 Health care contacts 
The 25 cases had 561 healthcare contacts (admissions to hospital and outpatient visits) during 
the follow-up period: a mean of 22 contacts per patient (range, 1–97; SD, 21.7). For the 474 
controls, the same figures were 4444 contacts, with a mean of 9 contacts per control (range, 
1–260; SD, 16.7). The difference was statistically significant (P = 0.007). 
9.4.2 Diagnoses/ICD-codes 
The numbers of unique ICD codes for cases and controls are presented in Table 15. 
On comparing all ICD codes together, there was no difference between the two groups. 
For the following ICD chapters, there was a significant difference:  
- Diseases of the blood and blood-forming organs (P = 0.023)  
- Endocrine and metabolic diseases (P = 0.045)  
- Disease of the nervous system (P = 0.001)  
- Diseases of the circulatory system (P = 0.000)  
- Diseases of the skin (P = 0.049)  
- Diseases of the musculoskeletal system (P = 0.000)  
To investigate the differences between the two groups, we performed a more in-depth 
analysis of the ICD chapters with significant differences. In ICD chapter 6 (nervous system), 
we found, quite surprisingly, that seven of the patients had a ICD codes for symptoms of the 
brachial plexus or carpal tunnel syndrome, with a frequency of 28%, compared to 1.5% for 
the controls. The difference in ICD chapter 8 (circulatory system) is explained by the follow-
up and monitoring of treatment of the thrombotic event. One patient had a registration for PE 
close to the thrombotic event. In chapter 12, comprising symptoms from the musculoskeletal 
system, there is an overrepresentation of ICD codes referring to different diagnoses 
comprising pain and discomfort in the upper extremity. For ICD chapters 3 (blood and blood 
organs), 4 (endocrine diseases), and 11 (skin diseases), there was no clear trend with a higher 
frequency of any ICD code. Most importantly, there was no difference between the two 
groups for ICD codes relating to malignancies. 
 40 
Table 15. Number and percent of unique ICD codes for each ICD group for patients and controls from the index 
point to the end of year. 
ICD chapter in ICD-10  Cases 
n        % 
Controls 
n          % 
P value 
1. Certain infectious and parasitic diseases yes 
no 
2 
23 
8% 
92% 
27 
447 
6% 
94% 
0.650 
2. Neoplasms  yes 
no 
4 
21 
16% 
84% 
77 
397 
16% 
84% 
1.0 
3. Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism  
yes 
no 
3 
22 
12% 
88% 
10 
464 
2% 
98% 
O.023* 
4. Endocrine, nutritional, and metabolic diseases yes 
no 
5 
20 
20% 
80% 
36 
438 
8% 
92% 
0.045* 
5. Mental and behavioral disorders  yes 
no 
5 
20 
20% 
80% 
39 
435 
8% 
92% 
0.059 
6. Diseases of the nervous system  yes 
no 
8 
17 
32% 
68% 
35 
439 
7% 
93% 
0.001* 
7-8. Diseases of the eye and adnexa and 
ear and mastoid process  
yes 
no 
5 
20 
20% 
80% 
86 
388 
18% 
82% 
0.792 
9. Diseases of the circulatory system yes 
no 
20 
5 
80% 
20% 
76 
398 
16% 
84% 
0.000* 
10. Diseases of the respiratory system yes 
no 
3 
22 
12% 
88% 
35 
439 
7% 
93% 
0.426 
11. Diseases of the digestive system yes 
no 
5 
20 
20% 
80% 
107 
367 
23% 
77% 
1.000 
12. Diseases of the skin and subcutaneous tissue yes 
no 
8 
17 
32% 
68% 
75 
399 
16% 
84% 
0.049* 
13. Diseases of the musculoskeletal system and connective 
tissue   
yes 
no 
15 
10 
60% 
40% 
113 
361 
24% 
76% 
0.000* 
14. Diseases of the genitourinary system yes 
no 
5 
20 
20% 
80% 
83 
391 
18% 
82% 
0.787 
15. Pregnancy, childbirth, and the puerperium yes 
no 
1 
24 
4% 
96% 
25 
449 
5% 
95% 
1.000 
16. Certain conditions originating in the perinatal period yes 
no 
0 
25 
0% 
100% 
0 
474 
0% 
100% 
1.000 
17. Congenital malformations, deformations, and chromosomal 
abnormalities 
yes 
no 
0 
25 
0% 
100% 
4 
470 
1% 
99% 
1.000 
18-21. Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 
Injury, poisoning, and certain other consequences of external 
causes 
External causes of morbidity and mortality 
Factors influencing health status and contact with health 
services 
Codes for special purposes 
yes 
no 
22 
3 
88% 
12% 
313 
161 
66% 
34% 
0.027* 
       
All ICD codes together yes 
no 
24 
1 
96% 
4% 
392 
82 
83% 
17% 
0.099 
 
In summary, this study shows that the rate of comorbidity for malignancies was in line with 
that of the general population and supports our and other authors’ opinion that primary 
UEDVT is a benign disorder; however, the cases had a higher number of healthcare 
contacts. 
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10 DISCUSSION 
The focus of this thesis is on primary upper extremity deep vein thrombosis, a rare disease. 
As described in the Introduction, our clinical question was: “How to handle patients with 
thrombosis of the arm?” What is the most appropriate treatment for our patients with primary 
UEDVT? A treatment that is based on science and proven experience. 
      Most previous studies comprise both primary and secondary UEDVT, which considerably 
complicates the interpretation of the results for primary UEDVT, in particular. In addition, 
there are very few prospective or randomized studies [44]. 
      The overall aim of this thesis was to increase the present knowledge of primary UEDVT 
regarding venous function, late sequelae, such as PTS, risk factors, recurrences, and 
comorbidity. In addition, we also wanted to investigate whether the anatomy of the upper part 
of the thorax has any role in the development of UEDVT. 
10.1 METHODOLOGICIAL CONSIDERATIONS 
The overall and main limitation of the studies is the small number of enrolled patients. The 
first three papers compromise 32 to 15 patients with primary UEDVT who were enrolled 
from 37 patients with primary UEVT that we found in the registers comprising 563 patients 
with UEDVT from two large hospitals in Stockholm during a period of ten years. This gives 
us a frequency of primary UEDVT of 7% of all UEDVTs. This is a lower incidence than 
Bleker et al.[44] describe in their review paper in which they state that one third of all 
UEDVTs are primary. One explanation of this might be that more than 4500 patients from 45 
studies are included. However, the 45 studies were very heterogeneous in terms of study 
design and study population. Other studies have shown that 20–25% of all UEDVTs are 
primary [57]. 
      Our intention for the fourth paper was to include a larger number of patients, randomly 
selected from the NPR data. The hypothesis was that, by selecting the ICD codes, we could 
achieve a high degree of conformity between the registry data and the patients’ medical 
records, but, unfortunately, this was not the case. The main reason for this is that there is no 
unique ICD code for UEDVT. There are unique codes for many other DVTs, but the codes 
I80.8 (Phlebitis and thrombophlebitis of other sites), I80.9 (Phlebitis and thrombophlebitis of 
an unspecified site), I82.8 (Embolism and thrombosis of other specified veins), and I8.29 
(Embolism and thrombosis of an unspecified vein) are used very frequently for all kinds of 
VTEs, instead of a more specific ICD code. Another finding is that a “DVT ICD code” is 
registered when a physician suspects a DVT on clinical grounds and more specific diagnostic 
examinations, such as CDU or venography conducted the following day, and the DVT 
 42 
diagnosis can often be written off, while the ICD code remains in the NPR. Therefore, it is 
extremely important to validate data based on the medical records. One study from Sweden 
and another from Denmark using the same search method found false positives with a rate of 
35–40% [2, 105]. In our study, the frequency of false positives was 95%, the difference being 
explained by the absence of a unique ICD code for primary UEDVT and by much wider 
inclusion criteria in the other studies, i.e., all kinds of thromboembolism.  
      The strength of all four papers is that only patients with primary UEDVT are included 
and, regarding the first three papers, we have been able to follow the patients over a long 
period of time: in Papers I and II for a mean period of 5 years (range, 2–9 years) and, in Paper 
III, for about 7 years (range, 3.6–11.3 years). Another strength of the studies is that all except 
one of the patients have been treated conservatively, with LMWH and VKA. For all patients, 
it was the first thrombotic event. 
10.2 GENERAL DISCUSSION AND MAIN FINDINGS 
10.2.1 Venous function 
Plethysmography was used to evaluate venous function. CDU, MRI, and the calculation of 
the area of the subclavian vein can also be regarded as measures of venous function. CDU 
can be used to provide both morphologic and hemodynamic information concerning patients 
with UEDVT [41, 106-108]. CDU has also come to replace phlebography more and more as 
the first line of diagnostics.  
      In our study, 58% of the patients had a residual thrombus, which is a higher figure than in 
a study by Sabeti et al. [60], which showed that 48% of the patients had a residual thrombus 
after a median follow-up period of 40 months. The difference is largely due to the fact that 
one third of the patients in their study underwent thrombolysis. Another study on patients 
with UEDVT and thrombolysis showed similar rates of residual thrombus to those of Sabeti 
et al. [109]. However, it seems that the frequency of residual thrombus is lower in the arms 
than in the lower extremities. A study by Johnson et al. [97] on LEDVT shows that only 
12% had normal duplex findings after a follow-up period ranging from one to six years. 
The results regarding the remaining occluded segments of the arm do not seem to differ from 
those reported after DVT in the lower extremity [110, 111]. 
      Our study did not show any patient with deep or superficial valvular insufficiency in the 
arms, which suggests that loss of valvular function is of less importance in developing PTS in 
the arms. 
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To obtain supplementary data to the morphologic information caught with ultrasonography, 
plethysmography was performed. The most evident result was that venous volume and 
venous emptying were significantly lower in the arms with a DVT than in the contralateral 
arm. Thirty-five percent had a venous emptying less than the lower normal limit, which is 
calculated as the mean of VE -2 SD, as presented in another study by our group [102]. This 
result is expected as the majority of the patients had residual vessel wall abnormalities and 
there was a clear trend toward lower venous emptying in patients with more advanced 
morphologic changes (Figure 12).  
 
 
Figure 12.  Venous emptying (VE) in relation to duplex category. The duplex categories used were 1, normal; 2, 
mild changes; 3, moderate-to-severe changes; and 4, occluded. The mean value for VE in each duplex category 
is indicated, and the lower limit of normality of VE is marked with a discriminating line. 
This finding was not significant and can be explained by the small number of patients in each 
ultrasound category. There are also other factors, such as stiff vessels, that can reduce venous 
emptying. In our study, four of 13 patients without a residual thrombus had a significant 
outflow obstruction as shown plethysmographically. Conversely, some patients with residual 
DVT and a still occluded vessel had normal venous emptying, probably due to the 
development of collaterals.   
      In the third paper, we used MRI to explore the anatomy in and around the subclavian 
vein. Regarding the area of the vein, we found a significant difference between the patients’ 
non-thrombotic arm and that of the controls with the arms raised over the head. This indicates 
that the anatomy plays a role in thrombus formation in the upper extremity. 
10.2.2 Postthrombotic syndrome  
The clinical entity of PTS includes a number of symptoms and clinical signs that are difficult 
to classify adequately. A number of factors are probably involved in the expression of this 
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syndrome, including both outflow obstruction and patient-related factors such as the degree 
of physical activity and physical demand. 
      The frequency of PTS in patients with UEDVT varies in different studies, probably due to 
heterogeneous study populations (both primary and secondary UEDVT), but also because of 
the use of different scales to measure the PTS. In this thesis, the modified Villalta scale is 
used and the same physician has evaluated all patients, also in the follow-up MRI study. 
There are difficulties in comparing our data with those of other studies because of mixed 
study populations. Our study showed a frequency of PTS of 28%, which is in line with PTS 
in patients with LEDVT [112]. One can assume that the frequency of PTS is lower in patients 
with primary UEDVT, compared to the secondary form; thus, most patients with secondary 
UEDVT often suffer from other medical conditions, i.e., malignancies, trauma, or indwelling 
catheters.  
      The patient group in the third paper had significantly elevated values according to DASH, 
while the modified Villalta test only showed severe signs of PTS in two patients. This may 
indicate that DASH, showing the patients’ subjective symptoms, is more sensitive than the 
modified Villalta test for the detection of the disability and discomfort of PTS in UEDVT. 
      Does PTS affect activities of daily living? Our results and those of others tend to point 
that way [86, 92]. We found a correlation between DASH and PTS measured with the 
modified Villalta scale. However, none of the patients reported that they had to change 
occupation after the thrombotic event, which is also shown in a study by Linblad et al.[15] on 
patients with primary UEDVT. 
      It is important to remember that, in our study, the majority of patients suffered only from 
mild-to-moderate PTS. It is interesting that, for the 15 patients in the follow-up study, the 
MRI study (two years later) showed almost similar results regarding both the Villalta scale 
and DASH on an individual basis. This indicates that the remaining symptoms are consistent 
over time. 
      In an attempt to further quantify the capacity of the arms, all patients performed an arm 
exercise test. Unfortunately, it was difficult to discriminate between the influence of PTS of 
working capacity and overall muscle capacity.   
10.2.3 Correlation between PTS and objective findings 
As mentioned in the Results section in Paper I, there was no significant association between 
the PTS score and the duplex findings, category 1 to 4, even though 58% had residual 
thrombi. Also with regard to plethysmography, the study did not show a statistical 
significance between PTS and venous function. A recently published study by Czihal et al. 
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[113] found neither a significant correlation between venous emptying and PTS nor between 
color duplex ultrasound findings and PTS. This of course raises the question of the cause of 
PTS. The limited numbers of patients included (31 in our study and 37 in the study by Czihal) 
limit the possibility of drawing a firm conclusion about factors of importance for the 
development of PTS. For patients with PTS and an almost normal venous outflow, collaterals 
play an important role, especially for those with a residual thrombus. Hence, one must 
consider whether or not color duplex ultrasound and plethysmography are the best methods to 
objectify PTS or whether the symptoms have an extravascular origin. Some authors have 
discussed the possibility of obtaining more information from arm volumetry and skin 
thickness. One can also consider if the Villalta score is the best way to quantify PTS. Further 
studies are needed. 
      The third paper comprising MRI confirms the results indicating no association between 
morphologic changes (i.e., in the area of the subclavian vein) and PTS. 
10.2.4 Coagulations disorders 
The prevalence of thrombophilia in our study was within the same range as for DVT in the 
lower extremities and at the same level as in other studies on UEDVT [36]. The most 
common thrombophilia in our study was the mutation of factor V Leiden. Unfortunately, we 
do not have the frequency of the mutation of the prothrombin gene; it was not determined in 
clinical practice when the majority of the patients had their thrombotic event. Interestingly, it 
seems that a moderate increase in fibrinogen is a common finding in this group of patients. 
The implication of this finding is unclear and calls for further investigation.  
      Elevated fibrinogen has been described as a risk factor for arterial thrombosis [114], but 
there are some studies that have shown an association between elevated levels of fibrinogen 
and DVT, while others have not [115].  
      In summary, our findings support the role of coagulation disorders as a risk factor for 
primary UEDVT. 
10.2.5 Recurrences and risk factors 
There is a pronounced variability between the recurrence rates, which range from 0% to 26% 
in different studies. Due to the fact that there are very few studies comprising only primary 
UEDVT, it is difficult to estimate the “real” frequency of recurrences, but several authors 
state that the recurrence rate for patients with primary UEDVT “should be lower.” 
      None of the patients in our study had a recurrent DVT or PE during the observation 
period, i.e., 5 years in the first two papers and 7 years for the patients who agreed to 
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participate in the MRI study. For all patients, the VKA treatment was stopped after six 
month. This is in line with a study by Lechner et al. [40], in which they only included primary 
VTE and followed 50 patients with primary UEDVT for an average of 59 months and 841 
patients with idiopathic lower extremity deep vein thrombosis (LEDVT) for 46 months. Only 
two patients (4%) in the UEDVT group had a recurrent VTE; for the LEDVT group, the 
recurrent rate was 15%.  
      So why is the risk of recurrence in primary UEDVT lower than in both secondary and 
idiopathic LEDVT?  
      In some respects, the higher rate of recurrences in the secondary group is explained by the 
underlying illness that most of these patients suffer from.  
     The different recurrence rate for idiopathic LEDVT has several explanations and the full 
picture is not known yet. The risk factors differs: patients with primary UEDVT tend to be 
slimmer and younger than patients with LEDVT. Both age and an increased BMI are risk 
factors for VTE. Furthermore, the location of the thrombi may influence the risk of getting a 
recurrent VTE. As mentioned earlier, the hydrostatic pressure is higher in the leg, there are 
more valves and, especially in the calf, a lot of muscle veins where the thrombus formation 
can start. It has also been shown that the fibrinolytic activity is higher in the arms.  
      The known risk factors for primary UEDVT, as found in our studies and the literature, 
can be summarized as thrombophilia (especially FV Leiden and the prothrombin mutation) 
and strenuous exercise with the arms by patients with narrowing of the thoracic outlet. The 
role of oral contraceptives remains unclear, but there is probably an association, especially 
when combined with thrombophilia. The use of oral contraceptives and HRT was as high as 
52% of the women in our study; this supports the theory that oral contraceptives do play a 
role. A family history of VTE seems to be lower in patients with UEDVT. 
      In Papers I–III, the typical patient was a woman (mean age 40) with a sedentary 
occupation and without any previous exceptional effort. This cannot of course explain the 
UEDVT, but the influence of one’s daily work perhaps calls for further studies. In Paper IV, 
there was no difference in the sexes, 48% males and 52% females. The study population was 
also older in Paper IV. Still, the study populations are too small to draw any conclusions. 
10.2.6 The anatomy of the upper thorax 
Narrowing and compression of the subclavian vein by surrounding structures has been 
described as risk factors for venous TOS and effort-related UEDVT. In our study, we found a 
narrowing of the thoracic outlet (costoclavicular distance) in both arms in the patient group 
when the arms were alongside the body.  
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      Interestingly, only one of the 15 patients was categorized as having effort-related 
UEDVT. This raises the question of whether external compression of the vein may be a more 
common cause of UEDVT than previously thought to be. Also, to our knowledge, there have 
not been any general, standardized questions about unusual and strenuous work with the arms 
before the thrombotic event. Thus, there probably is a relatively large variation in the 
meaning of “unusual and strenuous work with the arms,” which can lead to different reported 
percentages of effort-related UEDVT in different studies.  
     Our study further shows that the area of the subclavian vein (in the non-thrombotic arm) 
was smaller when the arm is in a supine position. This confirms the theory that especially 
working with the arms over the head can be a risk factor for UEDVT. 
      In summary, the costoclavicular space is narrower in a neutral position in the majority of 
patients with primary UEDVT than in controls. The importance of the costoclavicular space 
for developing UEDVT could be one explanation for why women are more exposed to 
UEDVT than men. 
10.2.7 Treatment 
All but one of the patients included in our studies were treated with LMWH and VKA; one 
patient received thrombolysis and was excluded from paper I. We have not found any 
convincing evidence in the literature that thrombolysis improves the long-term outcome of 
primary UEDVT. However, the relatively benign clinical outcome of patients with primary 
UEDVT suggests that a conservative approach is an acceptable choice in most cases and that 
more aggressive and potentially risky treatment can be an option in selected cases, such as 
those with extensive thrombosis and severe symptoms. 
10.2.8 Comorbidity 
This rather small study is, to the best of our knowledge, the first one in which comorbidity 
has been described in patients with primary UEDVT and compared with that of a control 
group which has been selected in the same way and can be seen as representing morbidity in 
the general population. The results in our studies support our theory that primary UEDVT is a 
rather benign disease. There was no difference between cases and controls in the reported 
diagnoses of malignancy. There was also no difference between patients and controls in the 
total unique diagnoses reported in the NPR, but there are differences in some ICD chapters 
that might be related to the thrombotic event. The cases had, however, a higher number of 
healthcare contacts than the controls. This can support data from studies on PTS and the 
reduction of the quality of life [86, 92].  
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11 CONCLUSIONS 
The overall aim of this thesis was to increase the current knowledge of primary upper 
extremity deep vein thrombosis. Based on the four papers, the following conclusions can be 
drawn: 
 Primary UEDVT is a rather benign disease with a low rate of recurrences, but with a 
non-negligible proportion of postthrombotic syndromes. The most common symptom 
is swelling of the arm. 
 More than 50% of the patients have residual thrombi and as many as 75% have some 
morphologic abnormality in the thrombotic vein that is detectable with CDU. The rate 
of venous emptying was significantly lower in the arms with DVTs than in the 
contralateral arms.  
 There is no correlation between PTS and plethysmographic findings, area of the 
subclavian vein, and morphologic abnormalities detected by CDU. 
 The frequency of coagulation disorders is about 40%, at the level with LEDVT.  The 
most common disorders in our study population are mutations of factor V and 
elevated fibrinogen. 
 There seems to be some influence between the anatomy of the upper thorax, 
especially the thoracic outlet, and the development of primary UEDVT, both effort- 
related and idiopathic. 
 The rate of comorbidity regarding malignancies seems to be in line with that of the 
general population. 
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12 IMPLICATIONS AND FUTURE PERSPECTIVES 
This thesis shows that primary UEDVT is a rather benign disease, but with a relatively high 
rate of postthrombotic discomfort for the patients. The cause of the thrombotic event is still 
unclear (idiopathic) for some patients. At the first thrombotic event, it is important to examine 
the patient thoroughly and look for coagulation disorders, listen to the patients’ history if 
there has been any vigorous or unusual exercise prior to the event. We know that malignancy 
is associated with DVT and therefore has to be ruled out.  
      The first choice for treatment should be LMVH and VKA, but thrombolysis should be 
considered for patients with severe symptoms. The best way of preventing PTS is to prevent a 
new thrombosis and therefore it is important to monitor the anticoagulant treatment 
accurately. 
      We, like other researchers, have not found any correlation between objective 
measurements of venous function and the postthrombotic syndrome. This raises questions 
about the origin of PTS. The patients report a feeling of heaviness and clumsiness in the 
affected limb, but we still do not have any objective methods to verify this feeling. Because 
of the nonassociation between PTS and the venous flow rate, the cause of PTS must be 
sought elsewhere. Is the cause on an extravenous level or are microcirculation or nervous 
symptoms involved? All of this requires further investigations. 
      The next step is to extend the numbers in Paper IV to determine if there is any difference 
from the general population regarding socioeconomic outcomes. This can be done by 
searching data on patients with verified primary UEDVT in the LISA register (Longitudinal 
Integration Database for Health Insurance and Labor Market Studies). This Swedish database 
integrates existing data from the labor market and educational and social sectors on an 
individual basis and is updated each year. Another finding is that there is extremely 
important, in future studies of UEDVT, to validate the PNR data with the medical records 
due to the fact that there is no unique ICD-code for UEDVT. 
 
      Most of all, a prospective study is wanted, but, because of the low incidence of primary 
UEDVT, there are difficulties in recruiting patients, and it must be done on a national basis. 
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13 SUMMARY IN SWEDISH 
BAKGRUND 
Djup ventrombos av den övre extremiteten (UEDVT) är en ovanlig sjukdom med en incidens 
av 1-11% av alla djupa ventromboser. UEDVT kan delas in i två grupper, primär och 
sekundär UEDVT. 
Primära UEDVT inkluderar idiopatisk och ansträngningsutlöst UEDVT, vilka i vissa studier 
står för upp till en tredjedel av alla UEDVT. Patienter med thoraxapertursyndrom 
klassificeras också som primär UEDVT. Sekundär UEDVT orsakas av till exempel katetrar 
eller pacemakersladdar i venerna. Vidare kan cancer och trauma mot övre extremiteten vara 
orsak till sekundär UEDVT. I vissa studier av patienter med UEDVT har förekomsten av 
cancer visat vara sig så hög som 38 %.  
Denna avhandling fokuserar på primär UEDVT. 
SYFTE 
Projektet startade som en klinisk frågeställning när vi skulle revidera vårdprogrammen för 
djup ventrombos vid vår akutmottagning. Frågan som vi ställde oss var: Hur gör vi med 
armtromboserna? Det första och på intet sätt vetenskapliga svaret var: Vi gör väl som vi gör 
med blodpropp i benen. Vid genomgång av tillgänglig forskning fick vi fler nya frågor än 
svar. Vissa forskare förordade aktiv behandling med trombolys medan andra förespråkade 
konservativ behandling med lågmolekylärt heparin och vitamin K-antagonist. 
Det övergripande syftet med denna avhandling är att öka kunskapen om primär 
armvenstrombos och genom denna kunskap kunna erbjuda framtida patienter adekvat 
behandling baserad på vetenskap och beprövad erfarenhet. 
PATIENTER 
Trettiotvå patienter (23 kvinnor, 9 män) med primär UEDVT rekryterades till studien, alla, 
utom en patient, behandlade konservativt med lågmolekylärt heparin och vitamin K 
antagonist. Femton av dessa patienter accepterade senare att delta i den tredje studien, magnet 
resonans tomografi studien, i vilken också en kontrollgrupp av 15 friska frivilliga nyttjades. 
Uppföljningsperioden för studie ett och två var 5 år och för studie tre 7 år. 
Den fjärde studien som är en registerstudie med data från Nationella Patientregistret (NPR) 
och omfattar 25 patienter med primär UEDVT, alla behandlade konservativt.  
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METODER 
Studie 1. Patienterna utvärderades genom intervjuer, klinisk undersökning, pletysmografi och 
färgduplex ultraljudsundersökning. Patienternas kvarvarande posttrombotiska symptom 
skattades med Villalta skalan som både tar hänsyn till patienternas kvarvarande symptom och 
kliniska fynd.  
Studie 2. Som komplement till Villalta skalan användes i denna studie DASH testet, ett 
frågeformulär som är validerat för att utvärdera funktionen i hand, arm och axel. VAS 
användes för att värdera smärta och nedsatt funktion. I ett försök att objektifiera 
arbetsförmågan genomgick alla patienter ett armcykeltest. Blodprover togs för antitrombin, 
protein C och S-brist, antifosfolipidantikroppar, mutation av faktor V Leiden, fibrinogen, D-
dimer, och von Willebrand-faktor-antigen. 
Studie 3. Anatomin av övre delen av thorax undersöktes med hjälp av MRI. Avståndet mellan 
nyckelbenet och första revbenet (det utrymme där v. subclavia passerar) uppmättes. Arean av 
v subclavia kalkylerades i samma lokalisation. Bägge beräkningarna gjordes med armarna 
både längs kroppen och uppsträckta över huvudet. Villalta och DASH genomfördes på nytt. 
Studie 4. De 25 patienterna matchades, på individuell basis, med 474 kontroller avseende 
kön, ålder vid indexhändelse och år för indexhändelse. Genom detta blev grupperna 
jämförbara även för observationstiden, tiden från indexhändelse till slutet av år 2011. 
Komorbiditet beskrevs som antalet unika ICD-koder (diagnoser) registrerade i NPR för 
patienter och kontroller från indexpunkten till slutet av år 2011.   
RESULTAT 
Studie 1. Ventömningshastigheten var signifikant lägre i armarna med trombos jämfört med 
den kontralaterala armen (P <.001). Femtioåtta procent av patienterna hade kvarvarande 
trombosrester i kärlet och 74% hade uppvisade någon morfologisk förändring. Det fanns 
inget statistiskt signifikant samband mellan pletysmografifynd och duplexundersökningen. 
De flesta (77 %) av patienterna rapporterade kvarvarande symptom i den drabbade armen, 
vanligaste besväret var svullnadskänsla i armen. Studien visade att det fanns en signifikant 
skillnad avseende omkretsen av överarmen mellan trombotisk och icke trombotisk arm. 
Ungefär en tredjedel av patienterna hade utvecklat en måttlig grad av posttrombotiska besvär 
enligt Villalta skalan. Ingen signifikant relation fanns mellan Villalta poäng och 
undersökningsfynden med ultraljud. Patienter med posttrombotiska symptom syndrom hade 
en lägre ventömningshastighet men skillnaden var inte statistiskt signifikant. 
Studie 2. Ingen av patienterna utvecklade malignitet, lungemboli, eller återkommande 
UEDVT. Tjugoåtta procent av patienterna hade milda till måttliga posttrombotiska symptom 
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enligt Villalta skalan. Förekomsten av trombofili var 40 % och den vanligaste avvikelsen var 
mutation av genen för Faktor V Leiden. Ett förhöjt fibrinogenvärde noterades också hos 22 % 
av patienterna. 
Studie 3. Avståndet mellan nyckelbenen och första revbenet var mindre hos patienterna när 
armarna var längs kroppen. Avseende arean av v. subclavia (jämförelse patientens friska arm 
och kontrollgruppen) fanns det en signifikant skillnad med armarna över huvudet. Det fanns 
en tydlig korrelation mellan Villalta och DASH men inte mellan Villata/DASH och MRI 
fynden. 
Studie 4. De 25 patienter och 474 kontrollerna, 48 % män och 52 % kvinnor, hade en 
medelålder vid indextillfället om 48 år (intervall 20-80, SD 17,5). Den genomsnittliga 
uppföljningstiden var 8 år (intervall 5,7-9 år). Patientgruppen hade signifikant flera hälso- och 
sjukvårdskontakter jämfört med kontrollgruppen. Det fanns ingen skillnad mellan grupperna 
avseende komorbiditet när alla ICD koder analyserades tillsammans. Däremot fanns skillnad 
för vissa kapitel (diagnosområden) av ICD-10. För ICD kapitel 3 (blod och blodbildande 
organ), 4 (endokrina sjukdomar) och kapitel 11 (hudsjukdomar) fanns det ingen tydlig trend 
med en högre frekvens av någon ICD-kod för patienterna. 
I ICD-kapitel 6 (nervsystemet) hade 7 av de 25 patienterna (28 %) ICD-koder för symtom 
från plexus brachialis eller karpaltunnelsyndrom, för kontrollerna var motsvarande siffra 1,5 
%. Skillnaden i ICD kapitel 8 (cirkulationssystemet) kan förklaras av uppföljning och 
monitorering av behandlingen av den initiala trombosen. En patient (4 %) patient hade 
registrerad ICD-kod för lungemboli. 
I kapitel 12, innefattande symptom från rörelseapparaten, fanns en överrepresentation av 
ICD-koder som hänvisar till olika diagnoser med smärta och obehag av den övre 
extremiteten. Viktigast fyndet var att det inte var någon skillnad mellan grupperna avseende 
ICD-koder som relaterar till malignitet. 
 
SLUTSATSER OCH DISKUSSION 
• Primär UEDVT är en godartad sjukdom med en låg grad av återfall men med en inte 
försumbar andel posttrombotiska symptom. Det vanligaste symptomet är svullnad av 
armen. Komorbiditeten avseende cancersjukdomar synes ej var förhöjd 
•  Sjuttiofyra procent av patienterna har kvarvarande förändringar i kärlet, diagnostiserat 
med ultraljudsundersökning. Ventömningshastigheten var signifikant lägre i armarna med 
trombos jämfört med den kontralaterala armen. 
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• Det finns ingen korrelation mellan graden av posttrombotiska symptom och objektiva 
mät- och undersökningsmetoder så som pletysmografi, ultraljud eller MRI 
undersökningsfynd varför orsaken till postrombotiska besvär måste sökas även utanför 
vensystemet. 
• Frekvensen av koagulationsrubbningar är 40 %.  
• Det verkar finnas ett samband mellan anatomin i övre delen av thorax och utvecklandet 
av UEDVT, både ansträngningsutlöst och idiopatisk. 
• För den absoluta majoriteten av patienterna med primär UEDVT är konservativ 
behandling med lågmolekylärt heparin och vitamin K-antagonist tillräckligt. 
• Komorbiditeten avseende cancersjukdomar synes vara i samma nivå som 
normalbefolkningen 
• Det är oerhört viktigt att validera registerdata med patienternas journal, framför allt om 
det inte finns en specifik ICD kod för den diagnos som skall studeras. 
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14 LEARNING AND OUTCOMES 
This project has been going on for several years, mostly because of a lack of time due to my 
regular work, first as clinician and later on as the head of the Emergency Department and 
Chief Medical Officer at our hospital. All the time, my goal was to finalize the project and 
write my thesis. The work has always been inspiring, even when the manuscripts were 
rejected, because it has been a way of learning both the subject and the scientific process. I 
have gained new knowledge on a range of scientific issues such as critical reviews of 
scientific publications, scientific thinking, hypothesis testing, statistics, writing a scientific 
paper and, most of all, I have learned to be patient. 
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